FDA grants accelerated approval to ponatinib combination for Ph+ ALL
The agency cleared Iclusig with chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia on March 19, 2024.
FDA
12 stories
The agency cleared Iclusig with chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia on March 19, 2024.
FDA
FDA approval of MIMRYLO triggered $275 million in payments to Protagonist, and the company plans a Phase 2b psoriasis study of PN-881 for early Q1 2027.
SEC filing
The company said it has FDA alignment on a registrational path for AATD drug WVE-006 and reported $431.0 million in cash as of September 30, 2026.
SEC filing (7)